GlaxoSmithKline PLC has said that it expects to be able to fill government orders for swine-flu vaccines by early 2010, but the company"s chief executive said production was going slower because the vaccine has yielded low levels of antigen, the ingredient that causes an immune response.Zanamivir the active ingredient in Relenza,will be in production over the next six months to replace supplies which are currently being used up because of the swine flu scare. The vaccine is due to be tested on a limited number of people weighing up risks of the vaccine against the danger of the pandemic.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지